Union européenne -
français -
EMA (European Medicines Agency)
beyfortus
astrazeneca ab - nirsevimab - des sérums et immunoglobulines, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.
Canada -
français -
Health Canada
beyfortus solution
astrazeneca canada inc - nirsévimab - solution - 50mg - nirsévimab 50mg
Canada -
français -
Health Canada
beyfortus solution
astrazeneca canada inc - nirsévimab - solution - 100mg - nirsévimab 100mg
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
beyfortus 50 mg/0.5 ml solution injectable en seringue préremplie
sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 50 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 0.5 ml. - prévention des maladies à rsv - biotechnologika
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
beyfortus 100 mg/1 ml solution injectable en seringue préremplie
sanofi-aventis (suisse) sa - nirsevimabum - solution injectable en seringue préremplie - nirsevimabum 100 mg, histidinum, histidini hydrochloridum monohydricum, arginini hydrochloridum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 1 ml. - prévention des maladies à rsv - biotechnologika